Solara Active Pharma Sciences Ltd (SOLARA) — shareholding pattern, promoter holding, financials and share price
About Solara Active Pharma Sciences Ltd (SOLARA)
Solara Active Pharma Sciences Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SOLARA and on the BSE under scrip code 541540. Its ISIN is INE624Z01016.
Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs. [1] It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent Scientific Ltd during the same time, making it a pure play API company. [2]
Solara Active Pharma Sciences Limited is a major manufacturer of active pharmaceutical ingredients (APIs), operating six plants with USFDA and other global regulatory approvals.
The company's ibuprofen business, once a major revenue driver, now faces significant challenges due to excess capacity and outdated processes, leading to financial strain.
Listed peers in Pharmaceuticals: Dishman Carbogen Amcis Ltd, Hikal Ltd, Kwality Pharmaceuticals Ltd, Sai Parenterals Ltd, Indoco Remedies Ltd, Beta Drugs Ltd.
Valuation & Returns
10 Jul 2026At ₹569.95 a share on 10 Jul 2026, Solara Active Pharma Sciences Ltd (SOLARA) was valued at a price-to-earnings ratio of -367.54x against an industry P/E of 36.41x and a price-to-book of 2.51x on a book value of ₹226.8 per share as of Mar 2025. Solomo computes return on equity of -0.68% and return on capital employed of 4.62% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -367.54x
- Industry P/E
- 36.41x
- P/B
- 2.51x
- EPS (TTM)
- ₹-1.54
- Book value / share
- ₹226.8
- ROE
- -0.68%
- ROCE
- 4.62%
- ROA
- -0.33%
- Debt / equity
- 0.73x
- Dividend yield
- 0%
- EBITDA margin
- 13.66%
- 52-week range
- ₹422.85 – ₹734.2
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Solara Active Pharma Sciences Ltd (SOLARA) reported revenue of ₹1,369 crore, net profit of ₹-7 crore and earnings per share of ₹-2.05. That compares with revenue of ₹1,284 crore and net profit of ₹1 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹387.29 crore and net profit ₹9.6 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,268 | 1,444 | 1,289 | 1,284 | 1,369 |
| Net profit (₹ cr) | -58 | -22 | -567 | 1 | -7 |
| EPS (₹) | -12.11 | -4.62 | -118.21 | 0.15 | -2.05 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | -0.58% | 0.40% | -0.40% |
| Profit growth | - | - | 100.10% |
| Stock price CAGR | -18% | 19% | -17% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 41.93% of Solara Active Pharma Sciences Ltd (SOLARA) (down 0.07 pp QoQ), foreign institutional investors (FII) hold 11.52% and domestic institutional investors (DII) hold 3.74%. Promoters have pledged 37.1% of their holding. Market capitalisation was ₹2,750 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2018.
Largest disclosed public shareholders in Jun 2026: AUTHUM INVESTMENT AND INFRASTRUCTURE LIMITED 3.78%, SPIRACCA VENTURES LLP . 3.54%, THE SCOTTISH ORIENTAL SMALLER COMPANIES TRUSTPLC 2.33%, HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD 2.17%, FSSA INDIAN SUBCONTINENT FUND AS SUB FUND OF FIRST SENTIER INVESTORS GLOBAL UMBRELLA FUND PLC 1.83%, TPG GROWTH IV SF PTE. LTD. 1.49%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 41.93% | 37.1% | 11.52% | 3.74% | 58.07% |
| Mar 2026 | 42% | 31.6% | 11.59% | 3.75% | 58% |
| Dec 2025 | 42% | 26% | 11.98% | 3.64% | 58% |
| Sep 2025 | 42.01% | 35.3% | 13.58% | 2.69% | 57.99% |
| Jun 2025 | 42.01% | 39% | 14.25% | 2.62% | 57.99% |
| Mar 2025 | 37.94% | 34.6% | 14.63% | 2.61% | 62.06% |
| Dec 2024 | 37.23% | 40.7% | 14.67% | 3.19% | 62.77% |
| Sep 2024 | 37.27% | 38% | 14.25% | 3.38% | 62.73% |